Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Enrollment (Screening)~1. Signed informed consent prior to initiation of any study procedures~2. Presence of an underlying medical condition(s) that might increase risk of complications from influenza~3. History of an influenza-like illness defined as:~   * One or more respiratory symptom (cough, sore throat, or nasal symptoms) AND~  * Either~  * Fever (subjective or documented \>38 degrees C) OR~  * 1 or more constitutional symptom (headache, malaise, myalgia, sweats/chills or fatigue)~4. Onset of illness no more than 96 hours before screening defined as when the subject experienced at least one respiratory symptom, constitutional symptom, or fever~5. Willingness to have samples stored~Randomization~1. Signed informed consent~2. Presence of a medical condition(s) that had been associated with increased risk of complications from influenza~   * Age 65 years of age or older~  * Asthma~  * Neurological and neuro-developmental conditions (including disorders of the brain, spinal cord, peripheral nerve, and muscle such as cerebral palsy, epilepsy \[seizure disorders\], stroke, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury) \[though still able to provide informed consent per inclusion criteria #1\]~  * Chronic lung disease (such as COPD and cystic fibrosis)~  * Heart disease (such as congenital heart disease, congestive heart failure, and coronary artery disease)~  * Blood disorders (excluding genetic causes of anemia, as noted in the exclusion criteria)~  * Endocrine disorders (such as diabetes mellitus)~  * Kidney disorders~  * Liver disorders~  * Metabolic disorders (such as inherited metabolic disorders and mitochondrial disorders)~  * Weakened immune system due to disease or medication (such as people with HIV/AIDS, or cancer, chronic steroids or other medications causing immune suppression)~  * BMI ≥ 40(kg/m²)~3. Onset of illness no more than 96 hours before screening defined as when the subject experienced at least one respiratory symptom, constitutional symptom, or fever~4. Positive test for influenza (either rapid antigen or PCR)~   - Results from influenza testing obtained for clinical indications within 12 hours before screening/enrollment may be used if available. Randomization may proceed in cases of discrepant results (one positive and one negative)~5. One of the following to avoid pregnancy:~   * Females who were able to become pregnant (i.e., are not postmenopausal, have not undergone surgical sterilization, and are sexually active with men) must agree to use at least 2 effective forms of contraception from the date of informed consent through 6 months after the last dose of study drug. At least one of the methods of contraception should be a barrier method~  * Males who had not undergone surgical sterilization and are sexually active with women must agree to use condoms plus have a partner use at least one additional effective form of contraception from the date of informed consent through 6 months after the last dose of study drug~6. Willingness to have samples stored~EXCLUSION CRITERIA:~(for Enrollment or Randomization)~1. Women who were pregnant or breast-feeding, and men whose female partner(s) was pregnant~2. Inability to take oral medication or a history of gastrointestinal malabsorption that would preclude the use of oral medication.~3. Hemoglobin \< 10 g/dL~4. WBC \< 1.5 times 10(9)/L~5. Neutrophils \< 0.75 x 10(9)/L~6. Platelets \< 50 x 10(9)/L~7. History of genetic hemoglobinopathy (e.g., thalassemia major or sickle cell anemia) or autoimmune hemolytic anemia~8. Received more than 2 doses of any antiviral influenza medications since onset of influenza symptoms~9. Received stavudine (d4T), didanosine (ddI), zidovudine (AZT), or azathioprine within 30 days prior to study entry~10. Creatinine clearance less than 60 mL/min (estimated by the Cockcroft-Gault equation using serum creatinine)~11. History of autoimmune hepatitis~12. Uncompensated liver disease (defined as AST \> 3 times site upper limit of normal (ULN), ALT \> 3 times ULN, or Direct Bilirubin \> 2 times ULN)~13. Clinical signs of end-stage liver disease including jaundice, coagulopathy, portal hypertension, esophageal varices, ascites, peripheral edema, gastrointestinal bleeding, or encephalopathy~14. Chronic liver disease categorized as Child-Pugh class C (Child-Pugh score 10-15)~15. Known hypersensitivity to rimantadine, amantadine, ribavirin, oseltamivir, peramivir, or zanamivir~16. Received live attenuated virus vaccine (influenza or other) within 3 weeks prior to study entry~17. Use of any investigational drug within 30 days or 5 half-lives (whichever was longer) prior to study entry~18. Participation in other research protocols that would require more than 100 mL of blood to be drawn in any 4-week period that overlaps with this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination Therapy (Type: EXPERIMENTAL): Amantadine, Ribavirin, Oseltamivir
- Oseltamivir monotherapy (Type: ACTIVE_COMPARATOR): Oseltamivir

Based on this trial design, predict the completion outcome and termination type (if applicable).